Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer Journal Article
| Authors: | Myskowski, P. L.; Halpern, A. C. |
| Article Title: | Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer |
| Abstract: | Advances in molecular biology have led to the successful development of targeted monoclonal antibodies to several types of malignancies. By June 2007, nine therapeutic monoclonal antibodies had been approved by the US Food and Drug Administration to treat various human cancers. In general, the adverse reactions of these agents have been milder than their cytotoxic chemotherapy counterparts, but side effects do occur. Cutaneous adverse reactions to the first of these agents were rare, and primarily limited to infusion reactions, local inflammation at injection sites, and ill-defined transient eruptions. However, the use of monoclonal antibody therapy against the epidermal growth factor receptor-1 in gastrointestinal and head and neck cancer has been frequently associated with significant skin reactions. As the use of these agents becomes more widespread, the recognition and management of these skin reactions becomes an increasingly important part of patient care. Copyright © 2008 by Current Medicine Group LLC. |
| Keywords: | antibiotic agent; unclassified drug; acute granulocytic leukemia; fludarabine; prednisone; clinical trial; drug tolerability; review; squamous cell carcinoma; bevacizumab; doxorubicin; fluorouracil; drug withdrawal; monotherapy; nonhuman; side effect; skin toxicity; solid tumor; treatment duration; antineoplastic agents; drug approval; paclitaxel; combined modality therapy; ibritumomab tiuxetan; rituximab; neoplasm; neoplasms; colorectal cancer; carboplatin; unindexed drug; edema; quality of life; drug eruption; breast cancer; bone marrow suppression; skin defect; lung non small cell cancer; mucosa inflammation; nausea; combination chemotherapy; alkylating agent; cyclophosphamide; vincristine; herpes simplex; herpes zoster; receptor, epidermal growth factor; cetuximab; irinotecan; monoclonal antibody; panitumumab; chill; drug fever; drug hypersensitivity; flushing; injection site reaction; pruritus; rash; wound healing; drug fatality; drug induced headache; hypotension; patient care; antibodies, monoclonal; hematologic malignancy; nonhodgkin lymphoma; rigor; folinic acid; acne; erythema; hair; nail; glucocorticoid; dermatitis; large cell lymphoma; platinum complex; immune deficiency; corticosteroid; trastuzumab; anthracycline; oxaliplatin; breast metastasis; dry skin; chronic lymphatic leukemia; tositumomab i 131; influenza; follicular lymphoma; drug binding; skin necrosis; retinoid; alemtuzumab; urticaria; hematologic disease; skin infection; skin ulcer; antihistaminic agent; gemtuzumab ozogamicin; angioneurotic edema; bacterial superinfection; desquamation; lichenoid eruption; opportunistic infection; papular rash; paronychia; skin allergy; skin fissure; stevens johnson syndrome; toxic epidermal necrolysis; xerosis; pustule; vesicular rash; campath 1 h; atopy; skin irritation |
| Journal Title: | Current Allergy and Asthma Reports |
| Volume: | 8 |
| Issue: | 1 |
| ISSN: | 1529-7322 |
| Publisher: | Springer Healthcare |
| Date Published: | 2008-01-01 |
| Start Page: | 63 |
| End Page: | 68 |
| Language: | English |
| DOI: | 10.1007/s11882-008-0012-z |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 17 November 2011" - "CODEN: CAARC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work